Document is current
Any future updates will be listed below
-
Authors
Keyl, Julius https://orcid.org/0000-0002-5617-091X
Keyl, Philipp https://orcid.org/0000-0002-5472-4683
Montavon, Grégoire https://orcid.org/0000-0001-7243-6186
Hosch, René
Brehmer, Alexander
Mochmann, Liliana
Jurmeister, Philipp
Dernbach, Gabriel
Kim, Moon https://orcid.org/0000-0002-7546-3910
Koitka, Sven
Bauer, Sebastian https://orcid.org/0000-0001-5949-8120
Bechrakis, Nikolaos
Forsting, Michael
Führer-Sakel, Dagmar
Glas, Martin
Grünwald, Viktor https://orcid.org/0000-0003-2083-7687
Hadaschik, Boris
Haubold, Johannes
Herrmann, Ken
Kasper, Stefan
Kimmig, Rainer
Lang, Stephan
Rassaf, Tienush
Roesch, Alexander https://orcid.org/0000-0002-0773-6067
Schadendorf, Dirk https://orcid.org/0000-0003-3524-7858
Siveke, Jens T. https://orcid.org/0000-0002-8772-4778
Stuschke, Martin
Sure, Ulrich https://orcid.org/0000-0002-9073-1821
Totzeck, Matthias
Welt, Anja
Wiesweg, Marcel https://orcid.org/0000-0002-9698-9559
Baba, Hideo A.
Nensa, Felix
Egger, Jan
Müller, Klaus-Robert https://orcid.org/0000-0002-3861-7685
Schuler, Martin https://orcid.org/0000-0002-2166-3394
Klauschen, Frederick https://orcid.org/0000-0002-9131-2389
Kleesiek, Jens https://orcid.org/0000-0001-8686-0682
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (FU 356/12-2, FU 356/12-2, 418179183 – KFO 337(RO 3577/3-2 (AR), RO 3577/7-1 (AR), SCHA 422/17-1 (DS))
Bundesministerium für Bildung und Forschung (BMBF; 01KD2206A/SATURN3, 01IS14013A-E, 01GQ1115, 01GQ0850, 01IS18056A, 01IS18025A and 01IS18037A)
- License Information
-
More Information
Article History
Received: 5 March 2024
Accepted: 6 December 2024
First Online: 30 January 2025
Competing interests
: V.G. receives honoraria from Bristol Myers Squibb, Pfizer, Ipsen, Eisai, Merck Sharp & Dohme (MSD) Oncology, Merck HealthCare, EUSAPharm, Apogepha and Ono Pharmaceutical; has an advisory role at BMS, Pfizer, MSD Oncology, Merck HealthCare, Ipsen, Eisai, Debiopharm, PCI Biotech, Cureteq and Oncorena; and received travel funding from Pfizer, Ipsen and Merck HealthCare. B.H. has an advisory role at ABX, AAA/Novartis, Astellas, AstraZeneca, Bayer, BMS, Janssen R&D, Lightpoint Medical and Pfizer; receives research funding from Astellas, BMS, AAA/Novartis, German Research Foundation, Janssen R&D and Pfizer; and receives travel funding from Astellas, AstraZeneca, Bayer and Janssen. D.S. receives personal fees for advisory boards of BMS, Immunocore, MSD, Neracare, Novartis, Pfizer, Philogen, Pierre Fabre, Sanofi and Regeneron; personal fees as an invited speaker from BMS, Merck Serono, MSD, Novartis, Roche and Sanofi; personal fees (financial interest) for steering committee membership from BMS and MSD; personal support (no financial interest) for steering committee membership from Novartis; institutional support as a coordinating principal investigator (no financial interest) from BMS, MSD, Novartis and Pierre Fabre; institutional support as a local principal investigator (no financial interest) from Philogen and Sanofi; institutional research grant support (financial interest) from BMS and MSD; and is an EORTC-MG Member of the Board of Directors (no financial interest). J.T.S. receives honoraria as consultant or for continuing medical education presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Immunocore, MSD Sharp Dohme, Novartis, Roche/Genentech and Servier; his institution receives research funding from Abalos Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisbach Bio and Roche/Genentech; and he holds ownership and serves on the Board of Directors of Pharma15, all outside the submitted work. M.T. receives speaker fees and personal support from AstraZeneca, Daiichi Sankyo, Novartis, Bayer, Asklepios and Edwards LifeSciences. M.W. receives honoraria and has an advisory role: Amgen, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, Takeda. Research funding: Bristol-Myers Squibb, Takeda. M.S. is a consultant (compensated) for Amgen, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck Serono, Novartis, Roche, Sanofi and Takeda; receives honoraria for CME presentations from Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, MSD, Novartis, Roche and Sanofi; and receives research funding (institutional) from AstraZeneca and Bristol-Myers Squibb. K.-R.M., F.K. and G.M. hold patents related to this work (9558550; 20180018553) and are co-founders of the computational pathology start-up Aignostics, Berlin. The remaining authors declare no competing interests related to this study.
